Cyber Alliances and Confluent Costs: IBM's Earnings Report Faces a Juggling Act
26.06.2026 - 16:17:32 | boerse-global.de
IBM is heading into its second-quarter earnings report on July 22 with a pair of strategic moves that tell two very different stories. On one hand, the company is forging a cybersecurity alliance aimed at countering the accelerating speed of AI-driven threats. On the other, it is still digesting roughly $18 billion in acquisitions — including the recently closed $11.6 billion purchase of Confluent — that are pressuring its balance sheet and earnings.
The security offensive brings together Palo Alto Networks, IBM, and Red Hat in a project called Lightwell. They are integrating Palo Alto's virtual patch technology to create a "shield-and-fix" workflow: Palo Alto blocks attacks at the network level while IBM and Red Hat repair the underlying software. The urgency is driven by the fact that AI-enabled threat actors now find and exploit vulnerabilities in minutes rather than weeks, according to Palo Alto CEO Nikesh Arora. The Lightwell initiative is backed by a multibillion-dollar budget for open-source security, targeting weaknesses in commercial applications, healthcare systems, and connected devices.
To ensure it has the financial firepower for such investments, IBM has extended two existing credit lines by one year each, maintaining a total capacity of $10 billion that now runs well into the next decade. This buffer comes as the company's long-term debt stood at $57.7 billion at the end of March, swollen by the Confluent cash deal. Management has warned that higher taxes, rising investment needs, and growing interest expenses could threaten its free-cash-flow targets.
Yet the top-line picture offers some encouragement. IBM's backlog for generative AI hit $12.5 billion by the end of 2025, and partnerships with names like OpenAI are fueling further momentum. The consulting business, while still sluggish, saw order inflows rise 6% recently, with generative AI making up about a third of the contract pipeline. Still, currency-adjusted consulting revenue grew only 0.9% in the first quarter, and CEO Arvind Krishna acknowledged that sales cycles are now longer than they were 18 months ago. A fresh competitive threat comes from Anthropic, whose "Claude Code" tool targets the same COBOL mainframe modernization work that is a lucrative revenue source for IBM's consulting arm.
Should investors sell immediately? Or is it worth buying IBM?
For the second quarter, analysts expect earnings of $3.00 per share on revenue of $17.85 billion. IBM itself has forecast software revenue growth of at least 10% for the year, consulting expansion in the low to mid-single digits, and a slight decline in infrastructure sales. The company also projects earnings dilution of roughly $600 million from the early Confluent close, a figure that could overshadow any operational outperformance.
At a current share price of €226.80, IBM stock sits about 4% below its 200-day moving average of €235.84. The 50-day line at €217.79 provides nearby technical support. The average analyst price target stands at €258.85, implying upside of more than 14% — but reaching that level will require the upcoming report to validate the bull case.
Optimists point to the strategic logic of the Confluent deal, which unites Apache Kafka with IBM's cloud offerings to eliminate data bottlenecks in large-scale AI workloads. The software segment already accounts for a growing share of revenue, and the $12.5 billion AI backlog suggests strong forward demand. A strict cost-cutting program that has saved billions since 2023 is also expected to support margins.
IBM at a turning point? This analysis reveals what investors need to know now.
Skeptics, however, see a risky integration timeline. IBM is absorbing both HashiCorp and Confluent almost simultaneously, and each brings an open-source developer culture that could clash with Big Blue's more bureaucratic approach. If customers become frustrated, they could migrate to alternatives like OpenTofu. Moreover, the $600 million dilution from Confluent is a concrete headwind that the company must explain away.
All eyes are now on July 22. If software growth hits the double-digit mark and consulting revenue shows a solid quarter-over-quarter pickup, the stock could test the 200-day line. But if the dilution proves heavier than expected or consulting growth stalls near zero, the recent recovery from the 52-week low of €181.32 will be put to the test. IBM needs every quarter from here on to beat its own forecasts — and a formal guidance upgrade in July would be the clearest signal yet that the gamble is paying off.
Ad
IBM Stock: New Analysis - 26 June
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
